Analysts polled by Capital IQ expected $1.20.
Revenue was $315.1 million for the quarter ended March 31, up from $311.7 million a year earlier.
Analysts surveyed by Capital IQ expected $319.5 million.
The company reaffirmed full-year 2022 adjusted non-GAAP diluted earnings of $6.52 to $6.79. Analysts surveyed by Capital IQ expect $6.68.
The company expects revenue of $1.5 to $1.54 billion for 2022. Analysts polled by Capital IQ expect $1.52 billion.
|-- Earnings Flash (AQS) AEQUUS PHARMACEUTICALS Repor...|
|Insider Buy: Bitnile Holdings|
|Insider Buy: Macerich|
|Insider Sell: Velodyne Lidar|
|Insider Sell: Xometry|